AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22640176 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic screening (history taking, physical examination, electrocardiography, spirometry, blood tests, and echocardiography)
Number of subjects: 0
Study 22640176 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 20718217 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 33
Study 20718217 — intervention group
Group type: COMPARATOR
Intervention: 0.243% sodium fluoride (negative control)
Number of subjects: 33
Study 20718217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing with either dentifrice
Number of subjects: 33
Study 20718217 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sodium fluoride dentifrice (during acclimation)
Number of subjects: 33
Study 18990996 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nonocclusal loading of dental implants
Number of subjects: 20
Study 18990996 — intervention group
Group type: COMPARATOR
Intervention: Early nonocclusal loading of dental implants (6 weeks)
Number of subjects: 20
Study 15385946 — intervention group
Group type: EXPERIMENTAL
Intervention: Est intervention
Number of subjects: 810
Study 15385946 — intervention group
Group type: EXPERIMENTAL
Intervention: Est Plus DASH intervention
Number of subjects: 810
Study 15385946 — intervention group
Group type: COMPARATOR
Intervention: Advice Only group
Number of subjects: 810
Study 12885699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 261
Study 12885699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 12885699 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity index
Number of subjects: 261
Study 12885699 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of initial body weight lost during the 6-month weight-loss phase
Number of subjects: 261
Study 10686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological measures including changes in lifestyle and dietary habits
Number of subjects: 60
Study 10686713 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care (Control)
Number of subjects: 60
Study 9124793 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice procedure with local anesthesia and antibio-prophylaxy
Number of subjects: 0
Study 1860285 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolin rinse
Number of subjects: 0
Study 1860285 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 7104143 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pindolol three times daily for 2 days
Number of subjects: 32
Study 7104143 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol three times daily for 2 days
Number of subjects: 32
Study 7104143 — intervention group
Group type: COMPARATOR
Intervention: Control group: young non‐smokers (YNS)
Number of subjects: 32
Study 30638922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Needle Tip Positioning (DNTP)
Number of subjects: 40
Study 30638922 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study 26250825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 871
Study 26250825 — intervention group
Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 871
Study 26853339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Radiation Therapy (RT) at a recommended phase 2 dose of 750 mg/m(2)/wk during the last 4 weeks of RT
Number of subjects: 29
Study 26853339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Radiation Therapy (RT)
Number of subjects: 29
Study 24408514 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cyperus rotundus oil
Number of subjects: 65
Study 24408514 — intervention group
Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 65
Study 24408514 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 65
Study 23022970 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month in patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Number of subjects: 360
Study 23022970 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 19457475 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust activation (view vomit images)
Number of subjects: 46
Study 19457475 — intervention group
Group type: COMPARATOR
Intervention: Neutral activation (view inanimate objects)
Number of subjects: 46
Study 19457475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 46
Study 19457475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline trait disgust propensity
Number of subjects: 46
Study 17486315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg)
Number of subjects: 12
Study 17486315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14977928 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Gamma Interferon (IFN-γ)
Number of subjects: 21
Study 14977928 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 21
Study 11450149 — intervention group
Group type: COMPARATOR
Intervention: CD4+CD45RA+/CD4+CD45RO+ cells ratio
Number of subjects: 0
Study 11450149 — intervention group
Group type: COMPARATOR
Intervention: Lymphocytes coexpressing CD45RA and CD45RO antigens
Number of subjects: 0
Study 10193294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 50 micrograms kg‐1 administered at the end of bypass
Number of subjects: 0
Study 7798858 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐minute double freeze
Number of subjects: 70
Study 7798858 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐minute double freeze
Number of subjects: 70
Study 7798858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐minute single freeze
Number of subjects: 70
Study 7798858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐minute double freeze
Number of subjects: 70
Study 3195756 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentration of anesthetic plus phenylephrine
Number of subjects: 60
Study 3195756 — intervention group
Group type: COMPARATOR
Intervention: Light anesthesia to maintain similar systolic blood pressures and stump pressures
Number of subjects: 60
Study 3195756 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 3195756 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 60
Study 30972657 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic amphetamine sulfate (RA-AMPH)
Number of subjects: 97
Study 30972657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 28550071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular discectomy
Number of subjects: 325
Study 28550071 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiscectomy
Number of subjects: 325
Study 25521304 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 100
Study 25521304 — intervention group
Group type: COMPARATOR
Intervention: Rupatadine
Number of subjects: 100
Study 22251553 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 18
Study 22251553 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 18
Study 21114690 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated fatty acid supplementation (0.25% caprylic and capric acid, 1:1)
Number of subjects: 48
Study 21114690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coated fatty acid supplementation (0.25% caprylic and capric acid, 1:1)
Number of subjects: 48
Study 21114690 — intervention group
Group type: COMPARATOR
Intervention: Coated fatty acid supplementation
Number of subjects: 48
Study 21114690 — intervention group
Group type: COMPARATOR
Intervention: Non-coated fatty acid supplementation
Number of subjects: 48
Study 17569583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (SP) loading (1g of tribasic dodecahydrate sodium phosphate, four times daily for 6 days)
Number of subjects: 6
Study 17569583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study 17569583 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 6
Study 16958396 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol of 150 ml of 300 mg I/ml
Number of subjects: 5
Study 16958396 — intervention group
Group type: COMPARATOR
Intervention: Protocol of 100 ml of 300 mg I/ml
Number of subjects: 5
Study 16958396 — intervention group
Group type: COMPARATOR
Intervention: Protocol of 100 ml of 350 mg I/ml
Number of subjects: 5
Study 12712353 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the motor nerve
Number of subjects: 8
Study 12712353 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical stimulation over the muscle belly
Number of subjects: 8
Study 11129986 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant tamoxifen (20 mg/day for 3 weeks)
Number of subjects: 107
Study 11129986 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 107
Study 9065902 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment (triptorelin) for 6 months
Number of subjects: 27
Study 9065902 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-ELL method
Number of subjects: 27
Study 9065902 — intervention group
Group type: COMPARATOR
Intervention: US-ELL measurements
Number of subjects: 27
Study 9065902 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoma SI patterns
Number of subjects: 27
Study 9065902 — intervention group
Group type: COMPARATOR
Intervention: MR and US comparison
Number of subjects: 27
Study 1640278 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1/2 unit per milliliter of continuous intravenous infusate or intermittent heparin flush)
Number of subjects: 113
Study 1640278 — intervention group
Group type: COMPARATOR
Intervention: No heparin (control group)
Number of subjects: 113
Study 1640278 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 113
Study 6713092 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloma morphology score (MMS)
Number of subjects: 0
Study 6713092 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloma progression score (MPS)
Number of subjects: 0
Study 29798783 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Number of subjects: 306
Study 29798783 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally interrupted apixaban
Number of subjects: 306
Study 29798783 — intervention group
Group type: EXPERIMENTAL
Intervention: All apixaban patients combined
Number of subjects: 306
Study 29798783 — intervention group
Group type: COMPARATOR
Intervention: Matched warfarin group
Number of subjects: 306
Study 26781590 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action (PA) program
Number of subjects: 1170
Study 25594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding pharmacists to primary care teams
Number of subjects: 123
Study 25594919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study 23080378 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline-based counseling intervention (CI) with up to 4 proactive telephone counseling sessions
Number of subjects: 410
Study 23080378 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH) group receiving only mailed cessation materials
Number of subjects: 410
Study 20945827 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized care condition
Number of subjects: 60
Study 20945827 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 60
Study 18371480 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (current smokers)
Number of subjects: 803
Study 18371480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 803
Study 18371480 — intervention group
Group type: COMPARATOR
Intervention: Age group comparison (18 to < 45 years vs > or = 45 years)
Number of subjects: 803
Study 16617225 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) rehabilitation program, 1-year duration, 13 sessions in small groups
Number of subjects: 207
Study 16617225 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 207
Study 12866653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-buffered CVVH (treatment A)
Number of subjects: 8
Study 12866653 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate-buffered CVVH (treatment B)
Number of subjects: 8
Study 10989857 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg clonidine
Number of subjects: 48
Study 10989857 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg clonidine
Number of subjects: 48
Study 10989857 — intervention group
Group type: COMPARATOR
Intervention: 0 microg clonidine (C0)
Number of subjects: 48
Study 9298044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 70
Study 9298044 — intervention group
Group type: COMPARATOR
Intervention: Office (manual) measurement
Number of subjects: 70
Study 8430965 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO) combined with methylprednisolone
Number of subjects: 75
Study 8430965 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone (placebo)
Number of subjects: 75
Study 3511776 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg albuterol
Number of subjects: 124
Study 3511776 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg albuterol
Number of subjects: 124
Study 3511776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 29170875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 212
Study 29170875 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 212
Study 26862930 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with esomeprazole (20 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) twice daily for 7 days
Number of subjects: 356
Study 26862930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with 5 days of esomeprazole (20 mg) and amoxicillin (1000 mg) twice daily, followed by 5 days of esomeprazole (20 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily
Number of subjects: 356
Study 26862930 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy with esomeprazole (20 mg), amoxicillin (1000 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily for 7 days
Number of subjects: 356
Study 25157002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 193
Study 25157002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 23255054 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention
Number of subjects: 57
Study 23255054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 21917187 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one peer support
Number of subjects: 0
Study 21917187 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence programme
Number of subjects: 0
Study 21917187 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one peer support and group reminiscence combined
Number of subjects: 0
Study 21917187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18251659 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care antimicrobial therapy after surgical incision and drainage
Number of subjects: 0
Study 18251659 — intervention group
Group type: COMPARATOR
Intervention: Placebo after surgical incision and drainage
Number of subjects: 0
Study 16482080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g per day for 7 days)
Number of subjects: 7
Study 16482080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 7
Study 16482080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin C and Placebo)
Number of subjects: 7
Study 16482080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 7
Study 14605529 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuvers (RMs) using continuous positive airway pressure of 35-40 cm H2O for 30 secs
Number of subjects: 72
Study 14605529 — intervention group
Group type: COMPARATOR
Intervention: Sham recruitment maneuvers
Number of subjects: 72
Study 14605529 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuvers (RMs)
Number of subjects: 72
Study 11038990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied to points: Touwei (ST 8), Xuanlu (GB 5), Fengchi (GB 20), Dazhui (GV 14), Lieque (LU 7), treated with the reducing method.
Number of subjects: 120
Study 11038990 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy (CDTG)
Number of subjects: 120
Study 11038990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 120
Study 11038990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 120
Study 8847442 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous obstructive apneas with hypoxemia
Number of subjects: 9
Study 8847442 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypoxemia (1-4 breaths of 100% nitrogen)
Number of subjects: 9
Study 8847442 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous obstructive apneas while breathing 100% oxygen (apnea without hypoxemia)
Number of subjects: 9
Study 8847442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic spontaneous obstructive apneas
Number of subjects: 9
Study 8847442 — intervention group
Group type: COMPARATOR
Intervention: Induced hypoxemia in control subjects
Number of subjects: 9
Study 1577051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose omeprazole (20 mg)
Number of subjects: 10
Study 1577051 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term omeprazole treatment (20 mg/day for 8 days)
Number of subjects: 10
Study 1577051 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 3086177 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 45
Study 3086177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 45
Study 3086177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31536624 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM annually at 0, 12, and 24 months
Number of subjects: 272
Study 31536624 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM semiannually at 0, 6, 12, 18, and 24 months
Number of subjects: 272
Study 31536624 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM+ALB annually
Number of subjects: 272
Study 31536624 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM+ALB semiannually
Number of subjects: 272
Study 31536624 — intervention group
Group type: COMPARATOR
Intervention: IVM annually
Number of subjects: 272
Study 31536624 — intervention group
Group type: COMPARATOR
Intervention: IVM semiannually
Number of subjects: 272
Study 30064027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF) therapy
Number of subjects: 1
Study 27587614 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIQ intervention
Number of subjects: 16
Study 27587614 — intervention group
Group type: COMPARATOR
Intervention: Booster intervention
Number of subjects: 16
Study 24627569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol treatment for 9 weeks
Number of subjects: 234
Study 22190354 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention
Number of subjects: 229
Study 20823377 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine-enriched cocoa (979 mg of theobromine)
Number of subjects: 42
Study 20823377 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural dose theobromine cocoa (106 mg of theobromine)
Number of subjects: 42
Study 20823377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18565218 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute risk reduction (ARR)
Number of subjects: 1169
Study 18565218 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction (RRR)
Number of subjects: 1169
Study 18565218 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat (NNT)
Number of subjects: 1169
Study 18565218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolongation of life (POL) without heart attack
Number of subjects: 1169
Study 18565218 — intervention group
Group type: EXPERIMENTAL
Intervention: All four formats combined with pictorial representation
Number of subjects: 1169
Study 18851773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 50
Study 18851773 — intervention group
Group type: COMPARATOR
Intervention: Applied relaxation (AR)
Number of subjects: 50
Study 18851773 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 50
Study 14643169 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 microg formoterol
Number of subjects: 20
Study 14643169 — intervention group
Group type: COMPARATOR
Intervention: 18 microg tiotropium
Number of subjects: 20
Study 14643169 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 microg formoterol + 18 microg tiotropium
Number of subjects: 20
Study 11522234 — intervention group
Group type: COMPARATOR
Intervention: CD56(+) cell expandability before CT1 and CT2
Number of subjects: 18
Study 11522234 — intervention group
Group type: COMPARATOR
Intervention: CD56(+) cell expandability after CT2 and G-CSF application
Number of subjects: 18
Study 11522234 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability after PBSC harvesting before CT3 and HDCT
Number of subjects: 18
Study 11522234 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability two weeks after autografting
Number of subjects: 18
Study 11522234 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability after recovery from autografting
Number of subjects: 18